HIGHLIGHTS
SUMMARY
Currently, available HPV vaccines protect against high-risk types of HPV (types 16 and 18), which account for approximately 70% of cervical cancers and vaginal, oral, and anal cancers. To prevent women from cervical cancer-related illness and mortality, the HPV vaccine is a better alternative than cytology screening or DNA testing, especially in resource-limited nations. Socio-demographic factors like gender and educational level, parents` occupation, participants` family members` history of cervical cancer, and participants who had information about the HPV vaccine (from school, newspaper, and internet) and fear of HPV infection were . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.